STERIS plc
NYSE: STE·Dublin, Ireland·CIK 0001757898
- Price
- $261.91
- Base IV
- $112.55
Valuation snapshot
At $261.91, the price is above even our bull case of $154.92.
Values per share, from an .
- No growth
- …
- Loading earnings power
- Base case
- $112.55
- 43% of the price · range $72.63–$154.92
- Price vs base case
- 133% above
- $261.91 against $112.55
- Base case · our researched forecast, 2026-11-15See the research ↗
- Price vs base · derived: price − base caseWhat the price expects ↗
- Price · StockValuer price feed, 2026-11-16 closeno link today
Whisker on the base case runs bear $72.63 to bull $154.92. Values per share.
Price against each value
- Bear case
- $72.63
- Price 261% above
- No growth
- …
- —
- Base case
- $112.55
- Price 133% above
What does Steris do?
STERIS provides healthcare providers and medical device manufacturers with sterilization equipment, cleaning chemicals, and outsourced reprocessing services to prevent infections and maintain medical instruments.
It brought in $6.2B of sales in the 12 months to Sep 2026.
- Industry
- Healthcare
- Based in
- Dublin, Ireland
- Trades on
- NYSE as STE
Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Sep 2026, about 13¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 55¢ of every dollar.
- Making what it sells55¢
- Research and development2¢
- Sales, marketing and admin23¢
- Interest and other costs1¢
- Tax5¢
- Left as profit13¢
Who pays Steris, and for what?
STERIS sells equipment, supplies and services that help hospitals prevent infection and help pharmaceutical and medical device makers sterilize and test products. It earns revenue from three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences.
Its customers are mainly hospitals and other healthcare providers, medical device makers, and pharmaceutical companies.
Healthcare
71%Equipment, infection prevention supplies, instrument repair and reprocessing services for hospitals and other healthcare providers.
STERIS AMSCO steam sterilizerPeterEasthope, CC BY-SA 4.0, via Wikimedia Commons Applied Sterilization Technologies (AST)
19%Contract sterilization and laboratory testing for medical device and pharmaceutical makers, plus sterilization equipment and support.
Life Sciences
10%Equipment, supplies and services that support pharmaceutical and medical device manufacturing, especially sterile production.
Where its work physically happens, beyond headquarters:
- Montgomery manufacturing facility — Montgomery, United States. This facility manufactures surgical tables, supplying capital equipment for STERIS’s healthcare business.
- Guadalupe sterilizer plant — Guadalupe, Mexico. The plant manufactures steam sterilizer and steam generator assemblies for STERIS’s equipment business.
- Québec sterile processing equipment plant — Québec City, Canada. The facility manufactures washing, disinfection, drying and sterile processing equipment for healthcare customers.
- Conroe endoscopy device facility — Conroe, United States. The facility manufactures disposable valves and sterile tubing sets used in endoscopy and general surgery.
- Tuusula Finn-Aqua facility — Tuusula, Finland. The facility manufactures decontamination, sterilization and water purification equipment for pharmaceutical and healthcare customers.
How is the business doing?
Sales grew from $3.1B in 2021 to $5.9B in 2026, about 14% a year.
Running the business leaves about 19¢ of each sales dollar as operating profit, about the same as 18¢ in 2021.
After paying for its upkeep and new investment, it had $937.2M of cash to spare in the 12 months to Sep 2026.
What does management say it's aiming for?
STERIS says it helps customers create a healthier and safer world by providing healthcare and life sciences products and services.
““WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD””
What management says it is working on now:
Grow the business
Management says it plans to grow through internal development of products and services and may add products and services through acquisitions.
STERIS plc 2026 Form 10-KInvest in capacity and efficiency
Management says it plans to invest in greater capacity and efficiency while managing costs. The company also announced a new North Carolina manufacturing and distribution center for formulated chemistries.
STERIS Announces Fiscal 2027 First-Quarter ResultsAdvance product development
The company says its development work is focused on sterile processing technologies, procedural products and accessories, and products used in gastrointestinal endoscopy.
STERIS plc 2026 Form 10-KImprove operations
STERIS says it applies continuous improvement practices across manufacturing, service, office and support work to improve performance and reduce waste.
STERIS plc 2026 Form 10-K
- Constant-currency organic revenue growth, Fiscal 2027
- 6%–7%
- STERIS Announces Fiscal 2027 First-Quarter Results
- Adjusted earnings per diluted share, Fiscal 2027
- $11.10–$11.30
- STERIS Announces Fiscal 2027 First-Quarter Results
- Capital expenditures, Fiscal 2027
- Approximately $450 million
- STERIS Announces Fiscal 2027 First-Quarter Results
- Free cash flow, Fiscal 2027
- Approximately $800 million
- STERIS Announces Fiscal 2027 First-Quarter Results
What's changing right now?
Growth is holding steady. In Q2 2027 it sold 9% more than a year earlier. The year before, quarters averaged 8%.
Its operating margin is about where it was a year ago, 19¢ per sales dollar.
Since Oct 2026 the share price has risen 13%, from $232.14 to $261.91.
Recently
November 4, 2026
Constant-currency organic revenue growth, quarterly YoY changed to 8.0%
STERIS Q2 FY2027 earnings releaseNovember 4, 2026
GAAP operating margin, fiscal second quarter changed to 18.5%
STERIS Q2 FY2027 earnings releaseAugust 5, 2026
Fiscal 2027 capital expenditure guidance changed to $450.0M
MarketBeat: STERIS issues FY2027 guidance
Coming up
Expected to begin operating in 2–3 years from August 2026
North Carolina formulated chemistries center
STERIS plans to invest $600 million in a manufacturing and distribution campus supporting infection prevention and contamination control products. The company expects the site to become operational in phases, beginning with distribution.
STERIS to Invest $600 Million in North Carolina Center of Excellence
Our own estimate moved too: the base case went from $150.79 to $112.55 a share between our last two valuations. The biggest reason: Fiscal 2027 capital expenditure guidance moved from an unreported prior value to $450.0M, as reported in MarketBeat: STERIS issues FY2027 guidance.
What could go wrong?
No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.
Competition and customer in-sourcing
STERIS faces competition from large and small companies, new technologies and products, and customers that may sterilize products in-house. This could pressure sales, pricing and results.
From the company's own filingsWould hit how fast sales growSTERIS plc 2026 Form 10-K
Regulatory approvals and compliance
Many products and operations need regulatory approvals and ongoing compliance. Delays, lost approvals or enforcement actions could disrupt sales, production or product launches and raise costs.
From the company's own filingsWould hit how fast sales growSTERIS plc 2026 Form 10-K
Customer budgets and healthcare funding
Hospitals and other customers may cut or delay purchases if economic conditions worsen or government healthcare funding and reimbursement decline. This could especially affect equipment demand and customer payments.
From the company's own filingsWould hit how fast sales growSTERIS plc 2026 Form 10-K
Trade policy and supply chains
Tariffs, trade restrictions or geopolitical disruption could raise costs, interrupt supplies or limit access to markets. The filing notes that ethylene oxide and cobalt-60, used in AST operations, have limited suppliers in some regions.
From the company's own filingsWould hit how much of each sale it keepsSTERIS plc 2026 Form 10-K
Product safety claims and recalls
Product liability claims, recalls or restrictions could bring costs, harm STERIS’s reputation and reduce product sales. Some claims or penalties may exceed insurance coverage or be uninsured.
From the company's own filingsWould hit how much of each sale it keepsSTERIS plc 2026 Form 10-K
Tax changes and disputes
Changes in tax laws, tax authority challenges and taxes on cross-border cash transfers could increase the company’s tax expense. STERIS says its future effective tax rate is uncertain.
From the company's own filingsWould hit the tax it paysSTERIS plc 2026 Form 10-K
The AST organic growth outlook was cut to 6–7%, and AST reported growth was only 5% in Q2.
From our researchWould hit how fast sales growFinviz Q2 FY27 analysis
Free cash flow of about $800–850M is guided for FY27, a high conversion of after-tax operating profit.
From our researchWould hit how much it has to reinvestSTERIS Q4 FY2026 earnings release
Is it a good business?
From 2019 to 2026 it earned between 2% and 10% on the capital invested in it, a median of 8%. Its cost of capital in the latest valuation is 9.1%; returns were above it in 2 of the 8 years.
From 2019 to 2026 it earned between 2% and 12% on its shareholders' equity, a median of 9%.
Over 8 years its operating margin ranged from 5¢ to 19¢ per sales dollar, a median of 16¢. Gross margin ran from 42¢ to 44¢.
Cost of capital 9.1%
It bought back shares: the count fell 1.2% in a year, so each remaining share owns a slightly bigger slice.
It owes $1.4B more than it holds in cash, about 1.2 years of operating profit.
What might it be worth?
The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .
Today a share costs $261.91. Our put its value between $72.63 and $154.92, with $112.55 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .
Bear case, $72.63
This scenario assumes STERIS's recent 7–9% sales growth fades to about 3% a year as a one-time surge in lab equipment orders passes, and its profits per dollar of sales slip a little below today's level.
Base case, $112.55
This scenario assumes STERIS keeps growing close to its recent pace of about 7–9% a year in the near term, slowing gradually to about 4–5%, while earning slightly more profit on each dollar of sales than it does today.
Bull case, $154.92
This scenario assumes STERIS keeps up something close to the 8–9% growth of its latest quarters for several more years and becomes steadily more profitable as its sterilization and lab businesses scale.
Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.
Why the gap?
The price expects far more than we do.Price above value: 133%
For Steris to be worth today's $261.91, sales would need to grow about 25.0% a year. We assume 5.5%. Over the last 5 years, sales grew 9.9% a year.
Or, if sales grow 5.5% as we assume, the price works with a profit margin of 43.6% (we assume 20.0%).
Keep in mind: investors are likely paying for things this model leaves out, such as new businesses or many more years of fast growth.
Do you think sales can grow 25.0% a year?
Try your own numbersWe're moderately sure of this range: it scores 63 out of 100 on our checks. The weakest point is terminal-value dependency.
Test the assumptions
Our base value of $112.55 rests on three assumptions. Change any of them to see how the value per share responds.
- Revenue growth, 5-year average5.5%
- Operating margin20.0%
- Long-term growth rate3.0%
This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.
Base estimate
$112.55 -57.0%


